**Core tip:** The angiotensin II type 1 receptor (AT~1~R) endogenously expressed in adrenocortical cells was known for decades to induce aldosterone production *via* a well-defined G~q~ protein-mediated signaling pathway. Over the past decade, a number of studies have elucidated another, β-arrestin-1 (βarr1)-dependent signaling cascade, which proceeds in parallel to, and independently of the G~q~-mediated one, and also results in aldosterone synthesis and secretion from the adrenal cortex. Importantly, although all of the Food and Drug Administration-approved angiotensin receptor blocker (ARB) drugs (AT~1~R antagonists) are very effective at blocking the G~q~-mediated pathway, as expected, since they were designed to do so (*i.e*., to block the G protein signaling of the AT~1~R), they seem to display varying efficacies at blocking this new, βarr1-dependent pathway, which translates into significant variation at aldosterone suppression efficacies. In that context, candesartan and valsartan appear the most effective agents at blocking also the βarr1 pathway emanating from the adrenocortical AT~1~R, and thus, these two agents may be the best aldosterone suppressors within the ARB drug class.

INTRODUCTION
============

Aldosterone is a mineralocorticoid hormone with several cardio-toxic actions, whose plasma levels are extremely high in chronic heart failure (HF) negatively affecting progression of the disease\[[@B1]\]. Amongst its main actions on the failing myocardium is overall promotion of adverse remodeling *via* maladaptive hypertrophy, chamber dilatation, collagen deposition and fibrosis, increased inflammation and reactive oxygen species production, *etc*. The net result of all of these effects is acceleration of cardiac functional decline\[[@B2]-[@B4]\]. The main source of circulating aldosterone is the adrenocortical zona glomerulosa (AZG) cells, which synthesize and secrete it in response to high serum K^+^ levels (hyperkalemia), since its main action on the kidneys is K^+^ excretion (along with Na^+^ and water reabsorption)\[[@B5]\]. Another powerful physiological stimulus for aldosterone secretion from AZG cells is the octapeptide hormone angiotensin II (AngII), which activates its type 1 receptors (AT~1~Rs), endogenously expressed in AZG cells\[[@B5],[@B6]\].

The AT~1~R is a 7-transmembrane-spanning or G protein-coupled receptor (GPCR); upon agonist activation, it couples primarily to the G~q/11~ family of G proteins\[[@B6]\]. Nowadays however, it is known to signal also through other types of G proteins, like G~i/o~ and G~s~, as well as through G protein-independent pathways mediated by the universal GPCR adapter proteins β-arrestin-1 (βarr1) and βarr2 (also known as arrestin-2 and -3, respectively)\[[@B7]-[@B9]\]. The βarrs bind agonist-activated and GPCR-kinase (GRK)-phosphorylated GPCRs to uncouple them from G proteins (receptor desensitization) and to target them to clathrin-coated vesicles for internalization (receptor endocytosis). At the same time, they initiate their own, "second wave" of signal transduction independently of G proteins\[[@B10]-[@B13]\].

ANGII-DEPENDENT ALDOSTERONE PRODUCTION: THE SUM OF TWO SIGNALING MODALITIES
===========================================================================

The G~q/11~ protein-dependent signaling pathway elicited by the AngII-activated AT~1~R that culminates in aldosterone synthesis and secretion in AZG cells has been well characterized (Figure [1](#F1){ref-type="fig"})\[[@B14]\]. More specifically, diacylglycerol (DAG) and inositol trisphosphate (IP~3~), the two second messengers produced by this pathway, ultimately lead to: (1) aldosterone secretion, *via* elevated intracellular free Ca^2+^ concentration, which directly stimulates exocytosis and hormonal (in the context of AZG cells, aldosterone) secretion; and (2) aldosterone synthesis, *via* extracellular signal-regulated kinase (ERK) MAPK activation, which, in turn, stimulate aldosterone biosynthesis in AZG cells by transcriptionally upregulating the StAR (steroidogenic acute regulatory) protein\[[@B14]\]. This protein mediates the mitochondrial uptake of the precursor of all adrenal steroids cholesterol and is the rate-limiting enzyme of aldosterone biosynthesis in AZG cells\[[@B14]\].

![Angiotensin II type 1 receptor and aldosterone production. Schematic representation of the parallel G prt- and βarr1-mediated, AngII-bound AT1R signaling cascades that converge on mitochondrial aldosterone synthesis in adrenocortical zona glomerulosa (AZG) cells. The structure of the proposed AT1R antagonist (2-pentyl-1-({4-\[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl\]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylic acid)\[[@B40]\], discussed in the text, capable of suppressing both pathways equally well, is also shown (upper left corner). See text for details. G prt: G~q~ protein; βarr1: β-arrestin1; AngII: Angiotensin II; AT~1~R: AngII type 1 receptor.](WJC-9-200-g001){#F1}

In the chronic HF setting, adrenal GRK2 is upregulated and, along with βarr1, hyperphosphorylates and severely desensitizes the sympatho-inhibitory α~2~-adrenergic receptors (ARs) of chromaffin cells in the adrenal medulla\[[@B15]-[@B21]\]. The result of this is chronic elevation of adrenal catecholamine secretion, which significantly contributes to the heightened sympathetic nervous system outflow and increased norepinephrine and epinephrine levels that further damage the failing heart\[[@B22]-[@B26]\]. Since aldosterone is also increased in HF and its production is stimulated by the AT~1~Rs of the adrenal cortex\[[@B1]\], which are also GRK2 and βarr1 substrates, it was theorized that the upregulated (in HF) adrenal GRK2 could lead to excessive interaction of βarr1 also with the AT~1~R in the adrenal cortex, thereby modulating aldosterone secretion in the chronic HF setting, as well. Indeed, this was found to be the case\[[@B27]\]. *Via* a combination of *in vitro* experiments in the human AZG cell line H295R and *in vivo* experiments in experimental rats developing HF following an acute, surgically induced myocardial infarction (MI), we were able to show that adrenal βarr1 actually promotes AngII-dependent aldosterone synthesis and secretion by also mediating AT~1~R signaling to ERK-dependent StAR upregulation independently of G proteins (Figure [1](#F1){ref-type="fig"})\[[@B27],[@B28]\]. This finding was somewhat surprising, given that βarr1 would normally be expected to reduce AngII-dependent aldosterone production thanks to desensitizing the AT~1~R (terminating its G protein-dependent signaling, see above). Nevertheless, it was discovered that, after abolishing the G~q~-dependent signaling by the AT~1~R in AZG cells, AT~1~R-bound βarr1 initiated its own signaling to aldosterone synthesis by recruiting a DAG-kinase to the activated receptor\[[@B29]\], which converted the second messenger lipid DAG to phosphatidic acid (PA)\[[@B27]\]. PA can directly activate the small (monomeric) G protein Ras at the plasma membrane, which then initiates the cascade that results in ERK phosphorylation and activation\[[@B30]\]. Thus, AT~1~R-activated βarr1 elicits a "second (delayed) wave" of signaling leading to sustained ERK activation in AZG cells in its own right (*i.e*., independently of G proteins), which, as discussed above, promotes aldosterone production *via* StAR upregulation\[[@B27]\]. Importantly, since StAR regulates synthesis not only of aldosterone but of all adrenal steroids throughout the three anatomical zones of the adrenal cortex\[[@B14]\], adrenal βarr1 may also affect the synthesis of glucocorticoids and of androgens in the adrenal cortex.

Notably, adrenal βarr1 may not only stimulate the AT~1~R-dependent aldosterone synthesis *via* its "second wave" of signaling to ERK-dependent StAR upregulation but also facilitate the acute AT~1~R-dependent aldosterone secretion at the plasma membrane of AZG cells and in parallel to the G protein-mediated signaling by the receptor (Figure [1](#F1){ref-type="fig"}). Recent evidence in transfected heterologous systems suggests such a role in the "first wave" of GPCR signaling for the βarrs\[[@B31],[@B32]\] and a very intriguing study, done specifically in the adrenal medulla, suggested an acute stimulation of catecholamine secretion and of Ca^2+^-dependent exocytosis by AT~1~R-activated βarr1 (but interestingly not by βarr2) in adrenal chromaffin cells, thanks to its direct interaction with the plasma membrane Ca^2+^ channel short transient receptor potential channel-3 (TRPC3)\[[@B33]\]. Thus, it is quite plausible that AT~1~R-bound βarr1 can directly stimulate TRPC3-dependent Ca^2+^ currents and hence, exocytosis, also in AZG cells, thereby acutely stimulating AngII-dependent aldosterone secretion within seconds of agonist binding (and in parallel to the G~q~-mediated signaling by the AT~1~R). This interesting possibility of another signaling mechanism by which βarr1 can induce aldosterone production in AZG cells is definitely worthy of investigation in future studies.

Most importantly, adrenal βarr1-dependent aldosterone production has been documented to occur also *in vivo*, both under physiological (in normal, healthy animals) and pathophysiological (in the post-MI HF setting) conditions\[[@B27],[@B28]\]. Specifically, adrenal-targeted βarr1 overexpression increased aldosterone serum levels *in vivo* in normal rats\[[@B27]\], and caused severe hyperaldosteronism also in post-MI rats on top of the circulating aldosterone elevation normally occurring due to the MI injury\[[@B28]\]. Importantly, in the latter animals, adrenal-specific βarr1 blockade *in vivo* with a βarr1 C-terminal fragment during post-MI HF progression helped stall the decline of cardiac function and even reversed several aspects/markers of adverse cardiac remodeling courtesy of normalization of circulating aldosterone levels\[[@B28]\]. What's more, aldosterone levels remarkably show no increase in βarr1-knockout mice post-MI, which further highlights the importance of adrenal βarr1 in regulation of circulating aldosterone levels\[[@B34]\]. Together, these *in vivo* studies strongly suggest adrenal βarr1, in conjunction with GRK2, as an attractive therapeutic target for diseases associated with, and aggravated by hyperaldosteronism, such as post-MI HF\[[@B9],[@B25]\]. Adding to its importance as a therapeutic target is also the fact that aldosterone can produce effects independently of its mineralocorticoid receptor (MR) (the so-called "non-genomic" actions of aldosterone)\[[@B4]\]. Obviously, these effects cannot be countered by MR antagonist drugs (*e.g*., eplerenone, finerenone, spironolactone) and thus, suppression of aldosterone production at its source, *i.e*., the adrenal cortex, *via* adrenal βarr1 blockade would be much more preferable from the therapeutic standpoint.

WHICH ARB DRUG WINS THE ALDOSTERONE SUPPRESSION "CONTEST"?
==========================================================

The realization that AngII-dependent aldosterone production from the adrenal cortex proceeds through two independent signaling modalities, *i.e*., G~q~ protein- and βarr1-dependent (Figure [1](#F1){ref-type="fig"}), signaled that complete blockade of both of these modalities is needed to attain full suppression of adrenal aldosterone production and effectively lower circulating aldosterone levels in HF and in other diseases. This, coupled with the fact that some AT~1~R antagonist drugs (angiotensin receptor blockers, ARBs, or sartans) appear ineffective at lowering aldosterone in HF, despite their full capacity to block AT~1~R-G protein coupling\[[@B35]-[@B38]\], prompted us to test the relative efficacy of the currently available ARBs at inhibiting the βarr1-dependent aldosterone production by the AT~1~R in an effort to identify the most effective agent(s). Indeed, the prototypic agent of this class, losartan, was found totally ineffective at preventing adrenal βarr1-dependent aldosterone production and combatting hyperaldosteronism post-MI due to very weak antagonism of βarr1 activation by the AT~1~R\[[@B28]\]. Interestingly however, the active metabolite of losartan EXP1374 was found quite effective at blocking AT~1~R-dependent aldosterone production and βarr1 activation\[[@B39],[@B40]\].

Upon subsequent head-to-head testing of all the currently Food and Drug Administration (FDA)-approved ARB drugs, it was found that, although all ARBs (including losartan) are potent inhibitors of G protein activation by the AT~1~R, their potencies at preventing βarr1 activation by the human AT~1~R *in vitro* varied enormously\[[@B40]\]. Specifically, candesartan and valsartan appeared the most potent blockers of βarr1 activation and the most efficacious aldosterone suppressors *in vitro* and *in vivo*\[[@B39],[@B40]\]. At the opposite end of the spectrum and in addition to losartan, was irbesartan, which was found to be a very weak βarr1 inhibitor and hence, a very ineffective aldosterone suppressor both *in vitro* and *in vivo*, despite its excellent G protein-blocking ability\[[@B39],[@B40]\]. The rest of the class fell more or less in the middle of the βarr1 inhibition and AT~1~R-dependent aldosterone suppression scales, *i.e*., their potency values were lower than candesartan's and valsartan's but much higher than losartan's and irbesartan's\[[@B39],[@B40]\]. Importantly, their effects on cardiac function of in post-MI HF animals *in vivo* were in complete concordance with their effects on circulating aldosterone levels; candesartan and valsartan induced significant improvements in cardiac function and remodeling post-MI, whereas irbesartan and losartan were not able to alter the course of progression of post-MI animals to full-blown HF\[[@B39]\].

IMPLICATIONS FOR HF PHARMACOTHERAPY
===================================

It is widely recognized nowadays that the members of the ARB drug class display significant variation in their pharmacological and clinical properties, which has significant repercussion for their use in HF pharmacotherapy\[[@B41]\]. In fact, certain agents have already been shown to afford larger improvements in morbidity and mortality of chronic HF than others\[[@B42]-[@B45]\]. Part of the reason for these differences among these agents that belong to the same pharmacological class and share the same mechanism of action (AT~1~R antagonism) may be differences in their efficacies at combating the hyperaldosteronism that accompanies and burdens chronic HF\[[@B1]\]. In other words, agents that suppress aldosterone effectively are bound to work better for HF therapy and, since adrenal βarr1 plays a pivotal role in regulation of this cardio-toxic hormone's levels, the ARBs that are most effective at blocking the AT~1~R-βarr1 interaction in the adrenal cortex would be expected to be preferred agents. In that vein, our aforementioned recent findings that candesartan and valsartan are the most efficacious βarr1 inhibitors at the AT~1~R, coupled with their excellent efficacy at lowering aldosterone *in vitro* and *in vivo*, point to these two ARBs as being the most preferable agents of their class to use in HF treatment (and in other hyperaldosteronic conditions, *e.g*., salt-sensitive hypertension). In contrast, irbesartan and losartan were found very weak βarr1-dependent aldosterone inhibitors, a finding that may have some bearing on the lack of therapeutic benefit of these two agents demonstrated in HF with preserved ejection fraction (HF-PEF) and on their therapeutic inferiority to candesartan in terms of HF mortality reduction\[[@B44],[@B45]\]. Of course, future trials providing data on the serum aldosterone levels of the ARB-treated HF patients are needed to confirm such a link between adrenal βarr1-dependent aldosterone suppression efficacy and clinical benefit for this important cardiovascular drug class.

On the other hand, failure of these agents to suppress aldosterone, otherwise referred to as "aldosterone breakthrough" or "aldosterone escape", is a clinically well-documented phenomenon\[[@B46]-[@B49]\] and the efficacy of each agent at inhibiting βarr1-dependent aldosterone production may be inversely proportional to the probability of the ARB to exhibit it. In other words, the more potent βarr1-dependent aldosterone suppressor an ARB is, the lower the likelihood is that the treated patient will suffer from "aldosterone breakthrough". Thus, candesartan and valsartan may be the safest ARB drugs to use in HF patients in terms of the risk of "aldosterone breakthrough". However, large trials closely monitoring the circulating aldosterone levels of treated patients are again needed in order to confirm this hypothesis.

IMPLICATIONS FOR AT~1~R BLOCKER MEDICINAL CHEMISTRY
===================================================

The studies on the relative potencies/efficacies of the currently FDA-approved ARBs at inhibiting AT~1~R-βarr1 interaction and βarr1-dependent aldosterone turnover provided some interesting medicinal chemistry and pharmacological insights, as well. Specifically, as far as the ARBs that are tetrazolo-biphenyl-methyl derivatives are concerned, which is a subgroup that includes losartan (and its metabolite EXP1374), irbesartan, candesartan, valsartan, and olmesartan, it was concluded that a substitution both bulky and negatively charged attached to the one side of the methylene group of the biphenyl-methyl backbone (the other end has the tetrazolo-biphenyl group attached) is needed to confer good inhibitory potency of βarr1 at the AT~1~R and consequently, effectively suppress aldosterone\[[@B40]\]. Indeed, both candesartan and valsartan, as well as EXP1374, have spacious, long aliphatic chain-containing and anionic (carboxylic acid) groups attached to that end of the biphenyl-methyl backbone\[[@B40]\]. In contrast, both losartan and irbesartan possess neutrally charged (unionizable) groups (albeit also bulky) at that biphenyl-methyl backbone end\[[@B40]\]. Finally, olmesartan, which also has an anionic (carboxylic acid) substitution but of intermediate bulkiness (*i.e*., less long aliphatic chain) compared to candesartan and valsartan on that side of its backbone, displays intermediate potency at inhibiting βarr1 activation and suppressing aldosterone\[[@B40]\]. Based on these observations, we have designed the compound 2-pentyl-1-({4-\[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl\]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylic acid (Figure [1](#F1){ref-type="fig"})\[[@B40]\], which carries a bulky, carboxyl acid group with a long aliphatic chain on the other end of the tetrazolo-biphenyl-methylene backbone, and we are currently testing both its potency at blocking βarr1 activation by the human AT~1~R and its efficacy at suppressing aldosterone secretion *in vitro* and in the post-MI HF setting *in vivo*. Our hope is that it will prove to be even more efficacious than candesartan and valsartan at suppressing aldosterone levels and thus, an even better drug for HF treatment than all currently available ARBs. Of course, the above mentioned ARB structure-activity relationship inferences have to be confirmed by crystal structure resolutions of the AT~1~R bound to βarrs. The first glimpse into the human AT~1~R crystal structure was recently provided and it was the first step towards that goal\[[@B50]\]. Unfortunately however, that crystal structure lacked the intracellular C-terminal tail of the receptor, which is exactly the AT~1~R region that interacts with βarrs \[[@B51]\].

CONCLUSION
==========

A head-to-head comparison of the ARBs currently on the United States market identified candesartan and valsartan as the most potent βarr1 antagonists and the most efficacious aldosterone suppressors at the human AT~1~R. Conversely, irbesartan and losartan were found to be largely G protein-"biased" inhibitors, with minimal efficacy towards inhibition of AngII-dependent aldosterone production. Thus, from a therapeutic standpoint, candesartan and valsartan may be the most preferable agents of this drug class, as they provide the biggest benefit for cardiac function and patient survival in post-MI HF and have the lowest propensity to cause the "aldosterone escape" adverse effect (failure to suppress aldosterone). Future studies on this class of drugs and on the effects of βarrs at the adrenal AT~1~R will help solidify these inferences and will also provide additional important information regarding AngII/AT~1~R pharmacology for clinicians and medicinal chemists alike.
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